Clinical Trials Logo

Cholangiocarcinoma clinical trials

View clinical trials related to Cholangiocarcinoma.

Filter by:

NCT ID: NCT02872831 Recruiting - Pancreatic Cancer Clinical Trials

Beacon BNX™ Endoscopic Ultrasound (EUS)-Needle vs SharkCore™ Needle

Start date: July 2016
Phase: N/A
Study type: Interventional

The primary objective of this proposed prospective randomized, multi-center study is to evaluate the capability of the new 22G SharkCore™ needle to obtain tissue specimens and to compare its performance against the standard 22G BNX Endoscopic Ultrasound Fine needle aspiration (Beacon Endoscopic, Newton, MA) needle in the evaluation of solid mass lesions in the pancreas and gastrointestinal tract. The secondary objective is to determine the ability of the 22G SharkCore™ needle system to yield histologic tissue.

NCT ID: NCT02856568 Not yet recruiting - Clinical trials for Unresectable Extrahepatic Bile Duct Carcinoma

Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma

Start date: October 2016
Phase: Phase 1
Study type: Interventional

This phase Ib trial studies the side effects and best dose of ricolinostat when given together with gemcitabine hydrochloride and cisplatin in treating patients with cholangiocarcinoma that cannot be removed by surgery or has spread to other places in the body. Ricolinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ricolinostat together with gemcitabine hydrochloride and cisplatin may work better in treating patients with cholangiocarcinoma that cannot be removed by surgery or has spread to other places.

NCT ID: NCT02836847 Recruiting - Gallbladder Cancer Clinical Trials

Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Start date: July 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the feasibility, efficacy and safety of target therapy according to genomic and proteomic profiling combined with GEMOX in advanced or recurrent extrahepatic cholangiocarcinoma and gallbladder carcinoma.

NCT ID: NCT02834780 Recruiting - Clinical trials for Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Start date: July 2016
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of H3B-6527 (Part 1), and to assess the safety and tolerability of H3B-6527 as a single agent administered orally (Part 2) in participants with advanced hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHCC).

NCT ID: NCT02834013 Not yet recruiting - Cholangiocarcinoma Clinical Trials

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Start date: June 2017
Phase: N/A
Study type: Interventional

This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT02807181 Not yet recruiting - Clinical trials for Intrahepatic Cholangiocarcinoma

CIS-GEM Chemotherapy+/- SIRT as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma

SIRCCA
Start date: September 2016
Phase: N/A
Study type: Interventional

The study will evaluate the benefit of applying Selective Internal Radiation Therapy (SIRT) using SIR-Spheres Y-90 resin microspheres prior to receiving systemic chemotherapy treatment (cisplatin-gemcitabine, or CIS-GEM) in patients with unresectable intrahepatic cholangiocarcinoma. Half of the patients will be randomized to CIS-GEM chemotherapy plus SIRT, and half of the patients will be randomized to CIS-GEM alone.

NCT ID: NCT02801500 Not yet recruiting - Clinical trials for Hilar Cholangiocarcinoma

Superior Bilioenteric Anastomosis by Magnetic Compressive Technique

CTREG
Start date: June 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether the magnetic compressive anastomosis has a better outcomes than traditional manual anastomosis on superior bilioenteric anastomosis.

NCT ID: NCT02798510 Recruiting - Clinical trials for Malignant Neoplasm Other Gallbladder/Extrahepatic Bile Duct

Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma

Start date: April 2016
Phase: Phase 3
Study type: Interventional

The present study is designed to determine whether adjuvant concurrent chemoradiotherapy improves overall survivals.

NCT ID: NCT02784795 Not yet recruiting - Breast Cancer Clinical Trials

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Start date: August 2016
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with other anticancer agents in participants with advanced or metastatic solid tumors.

NCT ID: NCT02773485 Recruiting - Cholangiocarcinoma Clinical Trials

Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma

Start date: May 2015
Phase: Phase 3
Study type: Interventional

The study evaluates impact of high dose radiation on overall survival in patients with unresectable nonmetastatic cholangiocarcinoma. The study randomizes patient between systemic chemotherapy alone and systemic chemotherapy and high dose radiation